10 Worst Blue Chip Stocks to Buy

6. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 68

% Decline on a YTD Basis: ~26.2%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.  Analyst John Newman from Canaccord Genuity maintained a “Buy” rating on the company’s stock and has a price objective of $850.00. The analyst’s rating is backed by several factors affecting its stock price. Despite the challenges related to the EYLEA product line, the analyst views potential in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s long-term growth prospects. Furthermore, the Factor XI program has also been highlighted as a significant opportunity by the firm’s analyst. Overall, the analyst’s positive outlook stems from the company’s ability to diversify revenue streams and capitalize on new market opportunities.

Coming to hematology, the company has been advancing its Factor XI program, where it continues to investigate 2 different antibodies targeting different factor XI domains in order to create a tailored approach to anticoagulation, providing potential for improved blood clot prevention and lower bleeding risk. In April 2025, the US FDA approved Dupixent for the treatment of adults and adolescents who are 12 years of age and older with CSU who remain symptomatic despite antihistamine treatment. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) also highlighted that, in March 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Dupixent for treating patients with COPD.

Baron Funds, an investment management company, released its Q3 2024 investor letter. Here is what the fund said:

“We purchased Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biopharmaceutical company that was built on a foundation in basic scientific research and antibody development. The company has successfully developed several blockbuster medicines, including Eylea and Eylea HD for retinal diseases (such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy) and Dupixent for immunological and inflammatory diseases (such as atopic dermatitis, asthma, and COPD). While Eylea is nearing the end of its patent life and faces potential biosimilar competition, the company has been transitioning patients to Eylea HD, which is a higher dose, longer-acting formulation of Eylea, and Dupixent is growing rapidly through indication expansion. Beyond the current product portfolio, Regeneron has an exciting new product pipeline with over 35 candidates in various stages of development, including a novel treatment for treating severe food allergy, a combination checkpoint inhibitor therapy for melanoma, lung cancer and other solid tumors, biospecific antibodies for blood cancers, and Factor XI antibodies for blood clot prevention, among others. Based on Regeneron’s track record of success discovering and developing new drugs, we are optimistic the pipeline will deliver some successes, which we think will drive upside in the stock.”